Treatment of low bone density in young people with cystic fibrosis: A multicentre, prospective, open-label observational study of calcium and calcifediol followed by a randomised placebo-controlled trial of alendronate

The Lancet Respiratory Medicine

Volumn 1, Issue 5, 2013, Pages 377-385

  Bianchi, Maria Luisa ^a   Colombo, Carla ^c,d   Assael, Baroukh M ^e   Dubini, Antonella ^b   Lombardo, Mariangela ^g   Quattrucci, Serena ^f   Bella, Sergio ^h   Collura, Mirella ⁱ   Messore, Barbara ^j   Raia, Valeria ^k   Poli, Furio ^l   Bini, Rita ^m   Albanese, Carlina V ⁿ   De Rose, Virginia ^o   Costantini, Diana ^c,d   Romano, Giovanna ^c,d   Pustorino, Elena ^g   Magazzù, Giuseppe ^g   Bertasi, Serenella ^f   Lucidi, Vincenzina ^h   Traverso, Gabriella ⁱ   Coruzzoa, Anna ^k   Grzejdziak, Amelia D ^p   more..

^a Centro Malattie Metaboliche Ossee   (Italy)

^b Laboratorio Analisi Chimico Cliniche   (Italy)

^c ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e Azienda Ospedaliero Universitaria di Verona   (Italy)

^f UNIVERSITY OF MESSINA   (Italy)

^g POLICLINICO UMBERTO I   (Italy)

^h BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

ⁱ Ospedale dei Bambini   (Italy)

^j SAN LUIGI GONZAGA UNIVERSITY HOSPITAL   (Italy)

^k UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^l INSTITUTE FOR MATERNAL AND CHILD HEALTH IRCCS BURLO GAROFOLO   (Italy)

^m MISERICORDIA HOSPITAL   (Italy)

ⁿ SAPIENZA UNIVERSITY OF ROME   (Italy)

^o UNIVERSITY OF TURIN   (Italy)

^p Medicina II   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; ALENDRONIC ACID; ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; CALCIFEDIOL; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; OSTEOCALCIN; PARATHYROID HORMONE; PLACEBO; BIOLOGICAL MARKER; BONE DENSITY CONSERVATION AGENT;

ADOLESCENT; ADULT; ARTICLE; BONE PAIN; CALCIUM INTAKE; CHILD; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FRACTURE; GASTROINTESTINAL DISEASE; HUMAN; HYPERCALCIURIA; ITALY; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; OBSERVATIONAL STUDY; OPEN STUDY; PARALLEL DESIGN; PATIENT COMPLIANCE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; BONE DENSITY; BONE REMODELING; CLINICAL TRIAL; COMPLICATION; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; LUMBAR VERTEBRA; METABOLISM; PHOTON ABSORPTIOMETRY; RADIOGRAPHY; TREATMENT OUTCOME; YOUNG ADULT;

ABSORPTIOMETRY, PHOTON; ADOLESCENT; ALENDRONATE; BIOLOGICAL MARKERS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; CALCIFEDIOL; CALCIUM; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LUMBAR VERTEBRAE; MALE; PROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84881378323     PISSN: 22132600     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2213-2600(13)70064-X     Document Type: Article

References (33)

1. Haworth CS. Impact of cystic fibrosis on bone health. Curr Opin Pulm Med 2010; 16: 616-22.
2. Papaioannou A, Kennedy CC, Freitag A, et al. Longitudinal analysis of vertebral fracture and BMD in a Canadian cohort of adult cystic fibrosis patients. BMC Musculoskelet Disord 2008; 9: 125.
3. Paccou J, Zeboulon N, Combescure C, Gossec L, Cortet B. The prevalence of osteopo rosis, osteopenia, and fractures among adults with cystic fibrosis: a systematic literature review with metaanalysis. Calcif Tissue Int 2010; 86: 1-7.
4. Bianchi ML, Romano G, Saraifoger S, Costantini D, Limonta C, Colombo C. BMD and body composition in children and young patients aff ected by cystic fibrosis. J Bone Miner Res 2006; 21: 388-96.
5. Grey V, Atkinson S, Drury D, et al. Prevalence of low bone mass and defi ciencies of vitamins D and K in pediatric patients with cystic fibrosis from 3 Canadian centers. Pediatrics 2008; 122: 1014-20.
6. Sermet-Gaudelus I, Castanet M, Retsch-Bogart G, Aris RM. Update on cystic fibrosis-related bone disease: a special focus on children. Paediatr Respir Rev 2009; 10: 134-42.
7. Conway SP, Oldroyd B, Brownlee KG, Wolfe SP, Truscott JG. A cross-sectional study of bone mineral density in children and adolescents attending a Cystic Fibrosis Centre. J Cyst Fibros 2008; 7: 469-76.
8. Javier RM, Jacquot J. Bone disease in cystic fibrosis: what's new? Joint Bone Spine 2011; 78: 445-50.
9. Hillman LS, Cassidy JT, Popescu MF, Hewett JE, Kyger J, Robertson JD. Percent true calcium absorption, mineral metabolism, and bone mineralization in children with cystic fibrosis: eff ect of supplementation with vitamin D and calcium. Pediatr Pulmonol 2008; 43: 772-80.
10. Hall WB, Sparks AA, Aris RM. Vitamin D deficiency in cystic fibrosis. Int J Endocrinol 2010; DOI:10.1155/2010/218691.
11. Conway SP, Oldroyd B, Morton A, Truscott JG, Peckham DG. Effect of oral bisphosphonates on bone mineral density and body composition in adult patients with cystic fibrosis: a pilot study. Thorax 2004; 59: 699-703.
12. Haworth CS, Selby PL, Webb AK, Mawer EB, Adams JE, Freemont TJ. Severe bone pain after intravenous pamidronate in adult patients with cystic fibrosis. Lancet 1998; 352: 1753-54.
13. Aris RM, Lester GE, Caminiti M, et al. Efficacy of alendronate in adults with cystic fibrosis with low bone density. Am J Respir Crit Care Med 2004; 169: 77-82.
14. Papaioannou A, Kennedy CC, Freitag A, et al. Alendronate once weekly for the prevention and treatment of bone loss in Canadian adult cystic fibrosis patients (CFOS trial). Chest 2008; 134: 794-800.
15. Sermet-Gaudelus I, Bianchi ML, Garabédian M, et al. European cystic fibrosis bone mineralisation guidelines. J Cyst Fibros 2011; 10 (suppl 2): S16-23.
16. Carter DR, Bouxsein ML, Marcus R. New approaches for interpreting projected bone densitometry data. J Bone Miner Res 1992; 7: 137-45.
17. Kroger H, Kotaniemi A, Vainio P, Alhava E. Bone densitometry of the spine and femur in children by dual-energy x-ray absorptiometry. Bone Miner 1992; 17: 75-85.
18. Cacciari E, Milani S, Balsamo A, et al. Italian cross-sectional growth charts for height, weight and BMI (2 to 20 yr). J Endocrinol Invest 2006; 29: 581-93.
19. Zoppi G, Bressan F, Luciano A. Height and weight reference charts for children aged 2-18 years from Verona, Italy. Eur J Clin Nutr 1996; 50: 462-68.
20. Genant HK, Wu CY, van Kuijk C, Nevitt MC. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 1993; 8: 1137-48.
21. D'Amicis A, Sette S, Turrini A, et al. Assunzione di calcio alimentare nei bambini italiani. Riv Sci Aliment 2004; 3: 99-106 (in Italian).
22. Reid IR, Bolland MJ. Risk factors: calcium supplements and cardiovascular risk. Nat Rev Cardiol 2012; 9: 497-98.
23. Curhan GC. Dietary calcium, dietary protein, and kidney stone formation. Miner Electrolyte Metab 1997; 23: 261-64.
24. Shead EF, Haworth CS, Barker H, Bilton D, Compston JE. Osteoclast function, bone turnover and inflammatory cytokines during infective exacerbations of cystic fi brosis. J Cyst Fibros 2012; 9: 93-98.
25. Le Heron L, Guillaume C, Velard F, et al. Cystic fi brosis transmembrane conductance regulator (CFTR) regulates the production of osteoprotegerin (OPG) and prostaglandin (PG) E2 in human bone. J Cyst Fibros 2010; 9: 69-72.
26. Bianchi ML, Cimaz R, Bardare M, et al. Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children: a prospective multicenter study. Arthritis Rheum 2000; 43: 1960-66.
27. Weinstein RS. Clinical practice. Glucocorticoid-induced bone disease. N Engl J Med 2011; 365: 62-70.
28. Sambrook PN, Rodriguez JP, Wasnich RD, et al. Alendronate in the prevention of osteoporosis: 7-year follow-up. Osteoporos Int 2004; 15: 483-88.
29. Garnero P, Darte C, Delmas PD. A model to monitor the efficacy of alendronate treatment in women with osteoporosis using a biochemical marker of bone turnover. Bone 1999; 24: 603-09.
30. Elkin SL, Vedi S, Bord S, Garrahan NJ, Hodson ME, Compston JE. Histomorphometric analysis of bone biopsies from the iliac crest of adults with cystic fibrosis. Am J Respir Crit Care Med 2002; 166: 1470-74.
31. Marshall D, Johnell OJ, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996; 312: 1254-59.
32. Melton LJ, Atkinson EJ, O'Connor MK, O'Fallon WM, Riggs BL. Bone density and fracture risk in men. J Bone Miner Res 1998; 13: 1915-23.
33. Eastell R, Vrijens B, Cahall DL, Ringe JD, Garnero P, Watts NB. Bone turnover markers and bone mineral density response with risedronate therapy: relationship with fracture risk and patient adherence. J Bone Miner Res 2011; 26: 1662-69.